ENB Therapeutics develops therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents.
ENB Therapeutics's investors include BioAdvance, Alexandria Venture Investments, Remiges Ventures, New York Ventures, Avestria Ventures.
ENB Therapeutics is headquartered in New York, United States.
ENB Therapeutics develops therapies to break barriers that prevent the majority of patients from responding to immunotherapy agents.
ENB Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ENB Therapeutics — Funding & Investors." VCBacked, January 3, 2022, https://www.vcbacked.co/company/enb-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). ENB Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/enb-therapeutics
{{cite web |title=ENB Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/enb-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated